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Syncope and the Risk of Adverse Outcomes January 22, 2013:325–32Prognosis Among Healthy Individuals Discharged With a
Primary Diagnosis of Syncope
Objectives This study sought to examine the risk of major cardiac adverse events and death in a nationwide cohort of pa-
tients without previous comorbidity admitted for syncope.
Background Syncope is a common clinical event, but knowledge of prognosis is not fully elucidated in healthy individuals.
Methods Patients without previous comorbidity admitted for syncope in Denmark from 2001 to 2009 were identified in nation-
wide administrative registries and matched by sex and age with 5 control subjects from the Danish population. The
risk of death or recurrent syncope, implantation of pacemaker or implantable cardioverter-defibrillator, and cardiovas-
cular hospitalization were analyzed with multivariable Cox proportional hazard models.
Results We identified 37,017 patients with a first-time diagnosis of syncope and 185,085 control subjects; their median
age was 47 years (interquartile range, 32 to 63 years) and 47% were male. A total of 3,023 (8.2%) and 14,251
(7.1%) deaths occurred in the syncope and the control population, respectively, yielding an event rate of 14.3
per 1,000 person-years (PY) in the syncope population. Multivariable Cox regression analysis demonstrated a
significantly increased risk of all-cause mortality (hazard ratio [HR]: 1.06; 95% confidence interval [CI]: 1.02 to
1.10), cardiovascular hospitalization event rate of 26.5 per 1,000 PY (HR: 1.74; 95% CI: 1.68 to 1.80), recurrent
syncope event rate of 45.1 per 1,000, stroke event rate of 6.8 per 1,000 PY (HR: 1.35; 95% CI: 1.27 to 1.44),
and pacemaker or implantable cardioverter-defibrillator event rate of 4.2 per 1,000 PY (HR: 5.52; 95% CI: 4.67
to 5.73; p  0.0001).
Conclusions The first admission for syncope among healthy individuals significantly predicts the risk of all-cause mortality,
stroke, cardiovascular hospitalization, device implantation, and recurrent syncope. (J Am Coll Cardiol 2013;61:
325–32) © 2013 by the American College of Cardiology FoundationSyncope is a common medical problem (1–4) that is difficult
to evaluate and is associated with a high mortality rate in
selected subgroups of patients (5–11).
The primary purpose of the evaluation of the patient with
syncope is to determine whether the patient is at increased
risk and implement preventive measures. Previous studies
have shown conflicting results regarding the risk of death,
and no data reflect the risk in syncope patients who are
otherwise healthy (i.e., no known cardiovascular disease or
comorbidity). The prognosis given in the different studies
varies significantly and depends on the setting and whether
it is the prognosis in the general population, in patients
examined in the emergency department (ED), or in patients
admitted to hospital with syncope (5,8–10,12–20).
See page 333
In addition, all studies had 1 thing in common: there was
a very high rate of unexplained syncope, which questions the
reliability of the true outcomes of syncope when dividing
into categories of etiology.
There is still a lack of evidence concerning the risk of
patients with syncope and no known comorbidity. To our
knowledge, no study has estimated mortality in a (pre)defined
subset of otherwise healthy syncope patients discharged from
hospital or sent home from the ED and compared this with a
representative background population. We investigated na-
tionwide registries of supposedly healthy syncope patients and
estimated their prognosis and time to future cardiac events.Methods
A personal and unique civil registration number (CPR
number) is assigned to all residents in Denmark that enables
linkage of nationwide administrative registries on the individ-
ual level. Information on all dispensed prescriptions from
Danish pharmacies since 1995 is registered according to the
Anatomical Therapeutic Chemical system in the Danish Reg-
ister of Medicinal Products (21). We obtained information on
hospitalization and comorbidities from the Danish National
Patient Register, where information on all hospital admissions
in Denmark has been stored since 1978 (22). At discharge,
each hospital admission is coded with 1 primary diagnosis and,
if appropriate, 1 or more secondary diagnoses according to the
International Classification of Diseases (ICD), before 1994,
the 8th revision, and from 1994 to date, the 10th revision
(ICD-10). Demographic information on date of birth, age,
sex, and vital status were obtained from the Danish Civil
Register.
Study population. From the Danish National Patient
Register, we identified all Danish residents with a first-time
admission to hospital or ED visit for syncope when classi-
fied as the primary discharge diagnosis (ICD-10 code
R55.9) between January 1, 2001, and December 31, 2009.
All hospital admissions, ED contacts, and nonacute referrals
(i.e., outpatients were included but each unique patient was
only recorded once). R55.9 refers to “syncope and collapse.”
Patients seen in the ED, given the discharge diagnosis of
R55.9, and immediately hospitalized were included if they
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January 22, 2013:325–32 Syncope and the Risk of Adverse Outcomesretained the diagnosis of R55.9 during the hospital admis-
sion and were discharged with that diagnosis. All secondary
diagnoses given at the same index hospitalization were
recorded. After identification, every syncope patient was
matched by age and sex with 5 random control subjects from
the Danish population. The control subjects were assigned
the same date of syncope as the case with which they were
matched (risk set matching). The “greedy macro match”
algorithm was used to identify the matched control popu-
lation (23).
Comorbidity and pharmacotherapy. Identification and
information on major comorbidities related to syncope up to
5 years before the index date for syncope admission or ED
visit were based on hospital discharge diagnosis codes
according to a modified Charlson Comorbidity Index
(24,25). We obtained information through the Danish
National Patient Register based on the primary or secondary
diagnosis for the following ICD-10 codes: cerebral vascular
disease (I60 through I69), ischemic heart disease (I20
through I25), previous myocardial infarction (I21, I22),
cardiac conduction disorders (I44, I45), atrial fibrillation
(I48, I49), other cardiac arrhythmias (I46, I47), heart failure
(I42, I50), chronic renal failure (N18, I12, I13), acute renal
failure (N17, N19, R34), pulmonary edema (J81), shock
(R57, A41), chronic obstructive pulmonary disease (J42
through J44), and cancer (C00 through C97). Hypertension
was defined as treatment. We identified patients with
hypertension from combination treatment with at least 2 of
the classes of antihypertensive drugs as defined in the
Online Appendix. This definition of hypertension was
validated in a previously described, randomly selected cohort
16 years of age and older from the Danish population (26).
We defined diabetes mellitus as a claimed prescription for a
glucose-lowering drug (A10) or admission for diabetes with
or without complications (E10 through E14).
Information on concomitant drug use up to 6 months
before syncope was provided through the Register of Me-
dicinal Product Statistics using the following Anatomical
Therapeutic Chemical system codes: statins (C10A), beta-
blockers (C07), angiotensin-converting enzyme inhibitors
(C09), loop diuretics (C03C), spironolactone (C03D), thia-
zides (C03A), calcium channel blockers (C08), digoxin
(C01A), class I antiarrhythmic drugs (C01BC), class III
antiarrhythmic drugs (C01BD and (C07AA), class IV
antiarrhythmic drugs (C08DA), morphine (N02AA),
glucose-lowering medication (A10), clopidogrel
(B01AC04), acetylsalicylic acid (B01AA0), vitamin K an-
tagonists (B01AA0), sedative and anxiolytic agents (N05B,
N05C), antipsychotic agents (N05A), and bronchodilators
(R04).
To define the population of patients with no comor-
bidity, we therefore excluded all patients who had been
hospitalized previously with any of the comorbidities
listed in Table 1 and who had claimed prescription of
selected pharmacotherapy within 180 days as defined in
the Online Appendix. galidation population. We
reviously validated the discharge
iagnosis of R55.9 and found a
ositive predictive value of 95%
nd a sensitivity of 61% (27).
utcome measures. Survival
tatus (whether patient is dead or
live) is obtained from the Na-
ional Person Register. Cause of
eath is obtained from the Na-
ional Danish Registry of Causes
f Death. The primary outcomes are long-term all-cause
ortality and within 1 year. Secondary outcomes are inser-
ion of an implantable cardioverter-defibrillator or pace-
aker, admission for stroke, or cardiovascular hospitaliza-
ion and admission for recurrent syncope. These outcomes
re gathered from the Danish Patient Registry according to
CD-10 discharge diagnosis and procedural codes.
tatistical analyses. Data are presented as number and
ercentage or mean and SD. Data not normal distributed
re presented as the median and interquartile range. Differ-
nces between categorical variables were analyzed with the
hi-square test and differences between continuous variables
ith the Wilcoxon rank sum test or the Kruskal-Wallis test.
Events and outcomes were individually evaluated and
hen analyzed by Cox regression analysis, competing model
nalysis, and cumulative incidence calculations. All models
ere tested for linearity of continuous variables. All analyses
ere done using SAS statistical software, version 9.2 (SAS
nstitute Inc., Cary, North Carolina).
thics. The study was accepted by the Danish Data Pro-
ection Agency (ref. 2007-58-0015, int. ref: GEH-2010-
01). Ethical approval is not required for registry-based
tudies in Denmark, and all data are anonymous and
ncrypted.
esults
e identified 88,335 patients with syncope, of whom
7,017 patients had no known previous hospitalization for
omorbidities and no concomitant use of selected pharma-
otherapy as listed in Table 1. The mean follow-up was 4.5
ears. The complete sex- and age-matched control popula-
ion comprised 185,085 individuals. The control group or
ackground population was likewise a low-risk population
ith a generally low rate of comorbidity. The matching was
nable to reach 100% due to the lack of control population
n the very high age groups. The complete matching
eached 99.73%. The median age was 47 years (interquartile
ange, 32 to 63 years), and 53% of the population were
omen.
-year mortality. The 1-year overall mortality rate was
.9% (696 deaths) in the syncope population and 2.0%
3,694 deaths) in the control population (p  0.1358). The
-year mortality rate was significantly increased in the age
Abbreviations
and Acronyms
CI  confidence interval
ED  emergency
department
HR  hazard ratio
ICD  International
Classification of Diseases
PY  person-yearsroups between 25 and 75 years, as depicted by the hazard
recept
onist.
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Syncope and the Risk of Adverse Outcomes January 22, 2013:325–32ratios (HRs) in Table 2. The youngest age group in the
syncope population only accounted for 1 death (0.0%),
whereas 26 deaths (0.2%) occurred in those between 25 and
One-Year Mortality HRsStratified by Age Groups Adjustedfor Sex, Age, Comorbidity, and Pharmacotherapy
Table 2
One-Year Mort lity HRs
Stratified by Age Groups Adjusted
for Sex, Age, Comorbidity, and Pharmacotherapy
Age Group, yrs HR 95% CI p Value
25 0.36 0.05–2.72 0.3201
26–44 2.02 1.27–3.21 0.0001
45–74 1.29 1.13–1.48 0.0001
75 0.89 0.83–0.96 0.0012
All age groups 0.94 0.87–1.02 0.1358
Baseline CharacteristicsTable 1 Baseline Characteristics
Characteristic Syncope
N 37,017
Men 17,304 (46.8
Women 19,713 (53.2
Comorbidity
Hypertension 0
Ischemic heart disease 0
Cerebral vascular disease 0
Previous myocardial infarction 0
Cardiac conduction disorder 0
Cardiac arrhythmia 0
Previous atrial fibrillation 0
Heart failure or pulmonary edema 0
Diabetes 0
Acute or chronic renal failure 0
COPD 0
Cancer 0
Liver disease, mild to severe 0
Concomitant pharmacotherapy
Statins 887 (2.4)
Beta-blockers 0
ACEI/ARB 0
Loop diuretics 0
Spironolactone 0
Thiazide 0
Calcium channel blockers 0
Antianginal agents 0
Digoxin 0
Class I antiarrhythmic 0
Class III antiarrhythmic 0
Class IV antiarrhythmic 0
Clopidogrel 0
ASA 1,053 (2.8)
VKA 0
Glucose-lowering drugs 0
Antipsychotic drugs 0
Anxiolytic drugs 3,754 (10.1
Bronchodilators 0
Morphine 728 (2.0)
Values are N, n (%), mean  SD, median (interquartile range), or p va
ACEI/ARB  angiotensin-converting enzyme inhibitor/angiotensin
pulmonary disease; IQR  interquartile range; VKA  vitamin K antagCI  confidence interval; HR  hazard ratio.44 years of age and 268 deaths (1.7%) occurred in those
between 45 and 75 years of age. There were 401 deaths
(8.8%) within 1 year in the oldest age group. The event rates
of all-cause mortality within the first year were 15.3 per
1,000 person-years (PY) in the syncope population and 16.3
per 1,000 PY in the control group.
Long-term mortality. The overall mortality was 8.2%
(3,023 deaths) in the syncope population and 7.7% (14,251
deaths) in the control population, with an HR of 1.06 (95%
confidence interval [CI]: 1.02 to 1.10) and a p value of
0.0033. The event rate for all-cause mortality was 14.3 per
1,000 PY for the syncope patients compared with 13.3 per
1,000 PY for the control subjects, and the mortality was
Controls Age (yrs), p Value
185,085 48.5 19.8, 47.0 (32–63)
98,565 (46.8) 50.1 18.2, 50.0 (36–63)
86,520 (53.2) 47.1 21.0, 45 (28–63)
17,584 (9.5) 0.0001
4,137 (2.2) 0.0001
2,995 (1.6) 0.0001
1,575 (0.9) 0.0001
418 (0.2) 0.0001
3,505 (1.9) 0.0001
2,805 (1.5) 0.0001
1,973 (1.1) 0.0001
5,644 (3.1) 0.0001
654 (0.4) 0.0001
1,947 (1.1) 0.0001
2,233 (1.2) 0.0001
436 (0.2) 0.0001
11,143 (6.0) 0.0001
11,842 (5.3) 0.0001
16,424 (7.4) 0.0001
7,251 (3.9) 0.0001
1,733 (0.9) 0.0001
10,966 (5.9) 0.0001
10,126 (5.5) 0.0001
2,825 (1.5) 0.0001
2,718 (1.5) 0.0001
147 (0.1) 0.0001
204 (0.1) 0.0001
1,216 (0.7) 0.0001
730 (0.4) 0.0001
11,092 (6.0) 0.0001
2,681 (1.5) 0.0001
5,644 (3.1) 0.0001
3,825 (2.1) 0.0001
19,026 (10.3) 0.4233
10.533 (5.7) 0.0001
3,442 (1.9) 0.1663
or blocker; ASA  acetylsalicylic acid; COPD  chronic obstructive)
)
)
lue.increased in the syncope population across all age groups
p
a
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January 22, 2013:325–32 Syncope and the Risk of Adverse Outcomesyounger than 75 years of age. The HR was 1.6 (95% CI: 1.03
to 2.68) in the youngest age group (younger than 25 years of
age) (Table 3). The HR in the age group ranging from 25 to
44 years of age was 2.29 (95% CI: 1.87 to 2.80). In the
middle-aged population (45 to 74 years of age), the HR was
1.23 (95% CI: 1.15 to 1.31) and 0.98 (95% CI: 0.94 to 1.01)
in the elderly. We found no significant difference in long-term
cardiovascular mortality between the 2 groups (event rate: 11.1
and 11.2 per 1,000 PY, p 0.4204). The cumulative incidence
lot in Figure 1 shows long-term mortality across age groups,
nd Figure 2 shows the cumulative incidence plot for the
selected age group of 45 to 74 years of age.
The development of cardiovascular comorbidity, stroke,
and the risk of device implantation after presentation of
first syncopal event in a healthy population. A total of
4,183 patients in the syncope population were hospitalized
for cardiovascular reasons. The event rate of cardiovascular
hospitalization was found significantly increased in the
syncope population, with an event rate of 26.5 per 1,000 PY
Long-Term Mortality HRsStratifi d by Age Group Adjustedfor Sex, Age, Comorbidity, and Pharmacotherapy
Table 3
Long-Term Mortali y HRs
Stratified by Age Groups Adjusted
for Sex, Age, Comorbidity, and Pharmacotherapy
Age Group HR 95% CI p Value
25 1.60 1.03–2.68 0.0197
26–44 2.29 1.87–2.80 0.0001
45–74 1.23 1.15–1.31 0.0001
75 0.98 0.94–1.01 0.2063
All age groups 1.06 1.10–1.17 0.0033
Abbreviations as in Table 2.
Figure 1
Cumulative Incidence Plot of Long-Term
All-Cause Mortality According to Age Groups in
Those With Syncope Compared With
Control Subjects
No significant difference in the risk of all-cause mortality was found in the age
groups older than 75 years and younger than 25 years of age. A significant dif-
ference in the risk of all-cause mortality was found in the age groups 25 to 44
years and 45 to 74 years.versus 15.3 per 1,000 PY, respectively (HR: 1.74; 95% CI:
1.68 to 1.80; p  0.0001). Similarly, we found an increased
risk of device implantation with an event rate of 4.2 per
1,000 PY versus 0.8 per 1,000 PY, respectively (HR: 5.52;
95% CI: 4.67 to 5.73; p  0.0001). The total amount of
implanted devices in the syncope population was 698. A
total of 1,131 patients experienced a stroke in the syncope
population, and the event rate of strokes was 6.8 versus 5.0
in the control population (HR: 1.35; 95% CI: 1.27 to 1.44;
p  0.0001). Data are presented in Figures 3 to 5.
Recurrent syncope. The event rate of recurrent syncope
was 45.1 per 1,000 PY. We saw an inverse relationship
between increasing event rates and decreasing HRs with
increasing age groups, as depicted in Table 4.
Discussion
This nationwide retrospective cohort study reveals novel
insights into the patterns of short- and long-term mortality
after an ED visit or admission for syncope in supposedly
healthy patients. First, we found a short-term increased risk
of death in the age groups between 25 and 74 years; however
measured in all age groups, only borderline significance was
noted between the 2 groups. Second, we found a signifi-
cantly increased risk of all-cause long-term mortality across
all age groups, and, finally, in our subgroup analysis, we
found a higher risk of death in those 44 to 75 years of age,
representing a group at especially increased risk. Further-
more, our results showed that syncope as a first symptom
significantly predicted several adverse outcomes such as an
increased risk of stroke, device implantation, and cardiovas-
Figure 2
Cumulative Incidence Plot of Long-Term
All-Cause Mortality in the Age Group 45 to 74 Years:
Syncope Versus Control Group
A significant difference in the risk of all-cause mortality in the age group 45 to
74 years indicates that this age group may have syncope as a first symptom of
future cardiovascular disease and adverse outcome.cular hospitalization.
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Syncope and the Risk of Adverse Outcomes January 22, 2013:325–32Not surprisingly, we found a very high event rate of
recurrent syncope that was also confirmed in the multivari-
able adjusted Cox regression analysis. However, the event
rate, in numbers not previously seen, describes very well
what is observed by clinicians—that the syncope patient is
seen in hospital several times and most likely is submitted to
Figure 4
Competing Risk Model of Patients With
Syncope Compared With Control Subjects and
the Cumulative Incidence of Implantation
of a Pacemaker or ICD
There was a significant difference in the risk of insertion of a pacemaker (PM)
or implantable cardioverter-defibrillator (ICD) when comparing syncope patients
and control subjects. The increase in risk was particularly dramatic within the
first year after discharge for syncope, after which the curves became parallel.
Figure 3
Competing Risk Model of Patients With
Syncope Compared With Control Subjects and the
Cumulative Incidence of
Cardiovascular Hospitalization
A significant difference in the risk of future cardiovascular hospitalization
across all age groups indicates that syncope in healthy individuals may be the
first symptom of future cardiovascular disease and increased hospitalization
compared with the background population.several tests, which have low diagnostic yield. Furthermore,
previous studies have shown that recurrent syncope in-
creases the risk of fractures and diminishes quality of life
markedly to levels of patients with rheumatoid arthritis and
epilepsy (16,17,28).
We defined the syncope population with no comorbidi-
ties according to their lack of hospitalizations in the previ-
ous 5 years combined with no use of selected prescription
drugs. The use of other prescription drugs in the syncope
group was low and did not exceed that by the control group
on any points. The increased rate of syncope among patients
with psychiatric disease was described previously, and anti-
psychotics in particular are associated with syncope, so we
chose to include this as a selected pharmacotherapy to
exclude from the study population (29–31). With regard to
the other types of drugs, we found significantly lower use
than in the control population. This supports that our
syncope population can be recognized as a presumably
“healthy” group. Generally, the use of prescription drugs in
the control population was likewise low, indicating that this
Figure 5
Competing Risk Model of Patients With
Syncope Compared With Control Subjects and
the Cumulative Incidence of Stroke
Stroke as an indicator of future cardiovascular disease was significantly
increased across all age groups in the healthy syncope population
compared with the control population.
Event Rates and HRs of RecurrentSyncope Stratified by Age Groups Adjustedfor Sex, Age, Comorbidity, and Pharmacotherapy
Table 4
Event ates and HR of Recurr nt
Syncope Stratified by Age Groups Adjusted
for Sex, Age, Comorbidity, and Pharmacotherapy
Age Group,
yrs
Event Rates per
1,000 PY HR 95% CI p Value
25 35.4 312.37 187.49–520.42 0.0001
26–44 38.7 545.70 343.10–867.94 0.0001
45–74 46.9 135.13 111.86–163.23 0.0001
75 74.7 37.75 31.94–44.63 0.0001
All age groups 45.1 118.27 105.38–132.73 0.0001PY  patient year; other abbreviations as in Table 2.
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January 22, 2013:325–32 Syncope and the Risk of Adverse Outcomesis representative of the background population and compar-
ison between the 2 groups is justified. Furthermore, we
assessed the secondary discharge diagnoses, and in only one
sixth of the syncope patients was there a secondary diagno-
sis, indicating that, as suspected, syncope was the primary
reason for admission and the prominent symptom during
the hospitalization. Important secondary diagnoses in terms
of mortality and relevancy to syncope relates to heart failure,
aortic stenosis, cerebral infarction, and ischemic heart dis-
ease. These secondary diagnoses are, in our data, very
limited in terms of absolute and relative numbers, and
relevant cardiovascular disease discovered during the actual
and first hospitalization, represented by secondary discharge
diagnoses, is low. The secondary diagnoses are given in
Online Table.
Syncope as a predictor of mortality in the young and the
elderly. We found a significantly increased risk of death in
the 25- to 44-year age group. This is important new
information not previously shown in larger studies. We
hypothesize that this group of patients may be underdiag-
nosed in terms of unrecognized cardiovascular disease re-
vealing a worse prognosis.
We found no significant association of increased all-cause
mortality or cardiovascular death in the elderly, but this may
largely be due to our control population. Therefore, it is
reasonable to assume that the true HR ratio of this subgroup
of our population would be higher if compared with a
control population of no comorbidity.
Mortality due to cardiovascular disease. Soteriades et al.
(5) followed 7,814 patients in the general population with
syncope for 17 years and found a higher mortality rate for
patients with cardiac syncope compared with noncardiac
syncope. Suzuki et al. (18) studied 912 patients with
syncope for an average of 3 years and found the same
result. A retrospective study of 1,516 patients showed,
however, no difference in the survival after syncope
between causes of syncope (divided into groups of unex-
plained, cardiovascular, and noncardiovascular) (8). Our
study fills a gap in knowledge, and the interpretation of
the increased risk in mortality in certain age groups
deserves extra attention. It may not be safe to rely on a
history of no comorbidity when evaluating a patient with
syncope, as some studies suggest.
A study comparing patients with and without syncope
matched for cardiovascular disease and other important
clinical variables found that cardiac syncope (per se) was not
a significant predictor of overall or cardiac 1-year survival
(10). Rather, underlying heart disease, particularly heart
failure, was found to be the significant survival predictor.
Likewise, a study of hospitalized syncope patients (8) found
that the risk of death was not associated with a cardiac cause
but correlated with age and comorbidity, which also in-
cluded cardiovascular diseases. In a study of patients with
advanced heart failure, poor left ventricular function was
associated with a high risk of sudden death, regardless of the
cause of syncope (19). Overall, there are discrepanciesregarding the mortality of syncope. Our study clearly indi-
cates that syncope as a first symptom in healthy people
represents an increased risk of death and may be the first
symptom of underlying cardiovascular disease.
This study is important to the clinician when evaluating
the prognosis of otherwise healthy individuals who have
experienced syncope. More studies, however, are needed
and, more importantly, proper risk stratification. Our study
particularly fills a gap in the evaluation of the healthy
younger and elderly who seem at the same risk as the
background population, where, however, more studies are
needed to clarify the much higher risk associated with the
middle age groups in terms of mortality and development of
cardiovascular disease.
Important strengths of the study include the long
follow-up period, the large size of our study sample, and the
fact that it was based on a nationwide unselected cohort of
patients with syncope in a clinical setting. The Danish
National Patient Register is the only nationally representa-
tive dataset that provides descriptive information about
Danish ED visits. By including information from nation-
wide registries, we minimize the risk of selection bias. This
study included patients independent of sex, socioeconomic
status, age, ethnicity and participation in insurance or health
programs and, importantly, included patients independent
of participation in the labor market. Validation of the
accuracy of a very similar ICD-9 (780.2) code in the United
States was performed by Gabayan et al. (32) (n  100),
demonstrating a positive predictive value of 92% and a
negative predictive value of 100%. In a substudy, we
validated 750 charts with the diagnosis R559 and found a
positive predictive value of 95% and 5,652 randomly se-
lected medical patients and found the sensitivity of syncope
to be 61%. This means that at least one third of the patients
hospitalized for syncope in the Danish registries are not coded
as syncope in the discharge diagnosis, which may create a bias
toward a more benign outcome as some cardiovascular syncope
cases are coded as specific cardiac causes (i.e., aortic stenosis or
ventricular tachycardia).
Study limitations. The main limitation is inherent in the
observational nature of the study and the lack of clinical
data, particularly, electrocardiographic data. The assump-
tion that the patients were without comorbidity was based
on the lack of hospital contact for comorbidities and on the
lack of use of selected pharmacotherapy. However, consid-
ering the fact that the patients did not take more medica-
tions for other conditions than the control group, we must
assume that they at least had no more comorbidities than
the control group. Our case ascertainment strategy could
not identify individuals with syncope who had an alternative
discharge diagnosis and did not have syncope coded as the
principal ICD-10 discharge diagnosis. Furthermore, it is an
inherent weakness that our outcome is based on hospital
discharge diagnosis rather than adjudicated events.
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Syncope and the Risk of Adverse Outcomes January 22, 2013:325–32Conclusions
First admission for syncope in a population without previ-
ous comorbidity significantly predicts the risk of all-cause
mortality, stroke, cardiovascular hospitalization, device im-
plantation, and recurrent syncope. The study suggests that
syncope in seemingly healthy persons may be a first symp-
tom of a more severe underlying cardiovascular disease.
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